loading page

An Overview of Noninvasive Ventilation in Cystic Fibrosis
  • +3
  • AESHA JOBANPUTRA,
  • Sugeet Jagpal,
  • Paula Marulanda,
  • MAYA RAMAGOPAL,
  • TEODORO SANTIAGO,
  • Sreelatha Naik
AESHA JOBANPUTRA
Rutgers Robert Wood Johnson Medical School

Corresponding Author:[email protected]

Author Profile
Sugeet Jagpal
Rutgers Robert Wood Johnson Medical School
Author Profile
Paula Marulanda
Rutgers Robert Wood Johnson Medical School
Author Profile
MAYA RAMAGOPAL
Rutgers Robert Wood Johnson Medical School
Author Profile
TEODORO SANTIAGO
Rutgers Robert Wood Johnson Medical School
Author Profile
Sreelatha Naik
Geisinger Wyoming Valley Medical Center
Author Profile

Abstract

Noninvasive ventilation (NIV) use was initially reported in cystic fibrosis (CF) in 1991 as a bridge to lung transplantation, and over the decades the use of NIV has increased in the CF population. Individuals with CF are prone to various physiologic changes as lung function worsens, and they may benefit from NIV for advanced lung disease. As life expectancy in CF has been increasing due to advances such as highly effective modulator therapy, people with CF are now subject to the same co-morbidities that may benefit from NIV as their age matched cohorts. NIV can improve gas exchange, quality of sleep, exercise tolerance and augment airway clearance in CF, and it is important that CF providers are comfortable with this therapeutic modality. In this review, we will summarize the physiologic basis for NIV use in CF, describe indications for initiation of NIV, and postulate a practical approach for CF clinicians to take fin monitoring patients on NIV. We will discuss aspects unique to people with CF and the use of NIV. We hope that this serves as a resource for CF providers, especially those of us who do not have dedicated training in sleep medicine, as we continue to care for our patient population.
01 Jun 2021Submitted to Pediatric Pulmonology
19 Jun 2021Submission Checks Completed
19 Jun 2021Assigned to Editor
20 Jun 2021Reviewer(s) Assigned
26 Jul 2021Review(s) Completed, Editorial Evaluation Pending
27 Jul 2021Editorial Decision: Revise Major
15 Sep 20211st Revision Received
15 Sep 2021Submission Checks Completed
15 Sep 2021Assigned to Editor
15 Sep 2021Reviewer(s) Assigned
10 Oct 2021Review(s) Completed, Editorial Evaluation Pending
11 Oct 2021Editorial Decision: Revise Minor
18 Oct 20212nd Revision Received
19 Oct 2021Submission Checks Completed
19 Oct 2021Assigned to Editor
19 Oct 2021Reviewer(s) Assigned
20 Oct 2021Review(s) Completed, Editorial Evaluation Pending
20 Oct 2021Editorial Decision: Accept
Feb 2022Published in Pediatric Pulmonology volume 57 issue S1. 10.1002/ppul.25753